Allient Inc.
ALNTAllient Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved +103.4% in a year while annual EPS moved +67.1% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is between stages. Underneath, the last four quarters read mixed, and 300% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Allient Inc. trades at $94.8, between stages. That is +26.5% against its own 200-day average. It sits at 74% of a 52-week range of $44 to $113. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (1 week and counting).
Today the stock is between stages. At $94.8 it trades +26.5% versus its 200-day average and sits at 74% of its 52-week range ($44–$113).
Against the market, two honest reads. Cumulative: over the last 1.2 years the stock moved +146% while the S&P 500 moved +21% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-09-11) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Allient Inc. trades at 55.7× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 55.7× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +67.1% against a +103.4% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Allient Inc. reads as turning around on its fundamental arc. Turning around — profit growth swung from −66.7% at the trough to +200.0%, a 3-quarter improving streak, ROCE holding at 7.7%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +3.8% | +3.2% | — | — |
| Profit | +100.0% | +0.0% | — | — |
| EPS | +67.1% | +6.6% | — | — |
| Stock price | +103.4% | — | — | — |
4-Factor Sector Score
56.0/100 — rank 5 of 30 in Electronic Components · 60% evidence confidence
Allient Inc. scores 56.0 out of 100 against the 30 companies it is compared with in Electronic Components, ranking 5. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 17.9 + 10.1 + 11.3 + 16.7 = 56. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Allient Inc. reported $0.1 B of revenue in the Mar 26 quarter, +7.7% year on year. That is the 3rd straight quarter of year-on-year growth. Over 4 years it has compounded at 8.3% a year. The last full year, FY25, came in at $0.6 B. The last four reported quarters add to $0.6 B.
FY25 revenue came in at $0.6 B (+3.8% on the year), capping 4 years at 8.3% compound. The latest quarter (Mar 26) printed $0.1 B, +7.7% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +8.0% growth against the decade's 8.3% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +7.7% over the last 4 quarters against −2.6%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Allient Inc.'s operating margin is 7.1% in the Mar 26 quarter, −0.6 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 5.7% to 7.5%. The current quarter sits inside that band.
The latest quarter's operating margin is 7.1%, −0.6 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 5.7%–7.5%.
🚨 Why the margin moved: operating margin went −0.6 pp year on year while gross margin went +4.9 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Allient Inc. earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The 4-year compound rate is 0.0%. That is 7.1% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.
Mar 26 profit was $0.0 B, null year on year. On the full year, FY25 printed $0.0 B (+100.0%), and the 4-year compound rate is 0.0%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 300% of Allient Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.1 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $0.1 B was left as free cash.
FY25: operating cash of $0.1 B against reported profit of $0.0 B, leaving free cash of $0.1 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 300% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Allient Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Allient Inc. earns a ROE of 7% in FY25. That is up from a trough of 4% in FY24. Return on invested capital clears the cost of that capital by −3.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 3.6% net margin on 0.95× asset turns.
FY25 ROE is 7%, recovered from a FY24 trough of 4% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): 3.6% net margin × 0.95× asset turns × 1.93× balance-sheet leverage ≈ 6.6% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 8.6% − 12.2% = a −3.6 pp spread. The 12.2% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Allient Inc. paid $0.12 per share over the last four reported quarters, up 20.0% on a year ago. The most recent declaration was $0.03 for Mar 26. Against the current price of $94.8 that is a trailing yield of 0.13%, measured on dividends already paid rather than on a forecast.
Allient Inc. paid $0.12 per share across the last four reported quarters, most recently $0.03 for Mar 26. That is up 20.0% against the same quarter a year earlier. Against the current price of $94.8 the trailing twelve months work out to 0.13% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Allient Inc. carries total debt of $0.2 B against shareholder equity of $0.3 B as of Mar 26, a debt-to-equity of 0.61. On the annual view that ratio went from 0.89 in FY21 to 0.67 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $0.2 B against shareholder equity of $0.3 B — a debt-to-equity of 0.61. On the annual view, debt-to-equity went from 0.89 (FY21) to 0.67 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
3.6% of Allient Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 2.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 3.6% of the float is sold short, and at typical trading volumes it would take about 2.0 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Allient Inc.: the Z-score reads 4.26. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 4.26 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 4.26.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Amphenol CorporationAPH | 70.8/100Favorable setup81% evidence | FADING | 24.7/35 Revenue 54.2% · PAT 61.8% · OPM change 4.2 pp 83% evidence | 21.3/25 ROCE 23.1% · OPM 29.8% 76% evidence | 14.7/20 P/E 42.2× · PEG 0.71 65% evidence | 10.1/20 RS sector -8.9% · RS bench 0.9% · 1Y 24.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 21.3 + 14.7 + 10.1 = 70.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Celestica Inc.CLS | 66.1/100Favorable setup81% evidence | ASLEEP | 26.7/35 Revenue 47.3% · PAT 100% · OPM change 0.4 pp 83% evidence | 16.9/25 ROCE 14% · OPM 9.8% 76% evidence | 15.5/20 P/E 37.8× · PEG 0.62 65% evidence | 7.0/20 RS sector -13.4% · RS bench -4.5% · 1Y 28%0 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 16.9 + 15.5 + 7 = 66.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Ralliant CorporationRAL | 58.7/100Thin evidence · provisional56% evidence | ASLEEP | 18.4/35 Revenue — · PAT — · OPM change 1 pp 39% evidence | 10.0/25 ROCE 2.1% · OPM 12.7% 76% evidence | 11.4/20 P/E 20.8× · PEG — 15% evidence | 18.9/20 RS sector 8.7% · RS bench 19% · 1Y 55.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 10 + 11.4 + 18.9 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Jabil Inc.JBL | 57.0/100Mixed-positive evidence81% evidence | ASLEEP | 20.7/35 Revenue 17.8% · PAT 49.2% · OPM change 0 pp 83% evidence | 14.3/25 ROCE 9% · OPM 5.1% 76% evidence | 13.8/20 P/E 45.5× · PEG 0.82 65% evidence | 8.2/20 RS sector -7.2% · RS bench 0.2% · 1Y 32.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 14.3 + 13.8 + 8.2 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Allient Inc.this pageALNT | 56.0/100Thin evidence · provisional60% evidence | FADING | 17.9/35 Revenue 8.7% · PAT 100% · OPM change 0.1 pp 53% evidence | 10.1/25 ROCE 1.8% · OPM 6.7% 57% evidence | 11.3/20 P/E 41.3× · PEG 1.47 65% evidence | 16.7/20 RS sector 17.7% · RS bench 26.7% · 1Y 103.4%10 of 12 weeks ahead 70% evidence |
| Exact sum: 17.9 + 10.1 + 11.3 + 16.7 = 56 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Knowles CorporationKN | 54.7/100Thin evidence · provisional56% evidence | ASLEEP | 20.1/35 Revenue — · PAT — · OPM change 7.4 pp 39% evidence | 9.1/25 ROCE 2.6% · OPM 10.4% 76% evidence | 9.5/20 P/E 53.9× · PEG — 15% evidence | 16.0/20 RS sector 4.3% · RS bench 12.6% · 1Y 55.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 9.1 + 9.5 + 16 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Methode Electronics, Inc.MEI | 54.6/100Mixed-positive evidence64% evidence | FADING | 18.9/35 Revenue -2.8% · PAT — · OPM change 12.9 pp 62% evidence | 5.2/25 ROCE 1% · OPM 3.7% 76% evidence | 11.2/20 P/E 21.4× · PEG — 15% evidence | 19.3/20 RS sector 19.9% · RS bench 27.6% · 1Y 65.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 5.2 + 11.2 + 19.3 = 54.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8CTS CorporationCTS | 54.4/100Thin evidence · provisional56% evidence | ASLEEP | 19.3/35 Revenue — · PAT — · OPM change 2.9 pp 39% evidence | 14.2/25 ROCE 3.9% · OPM 15.8% 76% evidence | 10.7/20 P/E 27.4× · PEG — 15% evidence | 10.2/20 RS sector -6.2% · RS bench 2% · 1Y 36.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 14.2 + 10.7 + 10.2 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Littelfuse, Inc.LFUS | 52.9/100Thin evidence · provisional56% evidence | ASLEEP | 19.1/35 Revenue — · PAT — · OPM change 2.7 pp 39% evidence | 12.0/25 ROCE 3.4% · OPM 15.4% 76% evidence | 9.4/20 P/E 54.9× · PEG — 15% evidence | 12.4/20 RS sector -1.8% · RS bench 5.6% · 1Y 50.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 12 + 9.4 + 12.4 = 52.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Sanmina CorporationSANM | 52.6/100Thin evidence · provisional56% evidence | ASLEEP | 18.7/35 Revenue — · PAT — · OPM change -0.7 pp 39% evidence | 13.3/25 ROCE 5.3% · OPM 3.9% 76% evidence | 9.9/20 P/E 42.3× · PEG — 15% evidence | 10.7/20 RS sector -3.3% · RS bench 4.7% · 1Y 65.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 13.3 + 9.9 + 10.7 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11M-tron Industries, Inc.MPTI | 51.9/100Thin evidence · provisional60% evidence | ASLEEP | 14.5/35 Revenue 9.8% · PAT 12.5% · OPM change 2 pp 53% evidence | 13.6/25 ROCE 4.9% · OPM 17.8% 57% evidence | 13.8/20 P/E 25.9× · PEG 0.98 65% evidence | 10.0/20 RS sector -3.9% · RS bench 4% · 1Y 44.9%6 of 12 weeks ahead 70% evidence |
| Exact sum: 14.5 + 13.6 + 13.8 + 10 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Plexus Corp.PLXS | 51.8/100Thin evidence · provisional56% evidence | ASLEEP | 16.6/35 Revenue — · PAT — · OPM change 0 pp 39% evidence | 11.7/25 ROCE 3.7% · OPM 5.3% 76% evidence | 10.3/20 P/E 40.6× · PEG — 15% evidence | 13.2/20 RS sector 1.8% · RS bench 8.9% · 1Y 71.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 11.7 + 10.3 + 13.2 = 51.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13TE Connectivity plcTEL | 50.7/100Mixed-positive evidence81% evidence | ASLEEP | 20.3/35 Revenue 16.5% · PAT 100% · OPM change 0.1 pp 83% evidence | 15.5/25 ROCE 4.8% · OPM 19% 76% evidence | 7.7/20 P/E 19× · PEG 3.07 65% evidence | 7.2/20 RS sector -23.2% · RS bench -13.4% · 1Y -6.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 15.5 + 7.7 + 7.2 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Benchmark Electronics, Inc.BHE | 50.7/100Thin evidence · provisional56% evidence | ASLEEP | 18.8/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 9.1/25 ROCE 2.1% · OPM 3.2% 76% evidence | 9.2/20 P/E 67.1× · PEG — 15% evidence | 13.6/20 RS sector 4.5% · RS bench 11.2% · 1Y 84%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 9.1 + 9.2 + 13.6 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Rogers CorporationROG | 49.3/100Thin evidence · provisional56% evidence | ASLEEP | 22.2/35 Revenue — · PAT — · OPM change 5.5 pp 39% evidence | 7.0/25 ROCE 1.5% · OPM 5.3% 76% evidence | 8.9/20 P/E 93.6× · PEG — 15% evidence | 11.2/20 RS sector -0.8% · RS bench 7% · 1Y 57.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 7 + 8.9 + 11.2 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Daktronics, Inc.DAKT | 47.8/100Thin evidence · provisional58% evidence | ASLEEP | 22.1/35 Revenue 10.8% · PAT — · OPM change 7.8 pp 62% evidence | 10.5/25 ROCE 4.1% · OPM 6.8% 76% evidence | 11.1/20 P/E 21.4× · PEG — 15% evidence | 4.1/20 RS sector -27.7% · RS bench -19.1% · 1Y -20.7%0 of 12 weeks ahead 70% evidence |
| Exact sum: 22.1 + 10.5 + 11.1 + 4.1 = 47.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Kopin CorporationKOPN | 47.3/100Thin evidence · provisional51% evidence | ASLEEP | 15.4/35 Revenue -23.5% · PAT — · OPM change -19.6 pp 40% evidence | 5.5/25 ROCE -12.6% · OPM -56.7% 57% evidence | 8.5/20 P/E 181.5× · PEG — 15% evidence | 17.9/20 RS sector 11.7% · RS bench 20.1% · 1Y 61.3%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.4 + 5.5 + 8.5 + 17.9 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Corning IncorporatedGLW | 45.3/100Mixed-negative evidence81% evidence | ASLEEP | 21.4/35 Revenue 19.4% · PAT 100% · OPM change 0.7 pp 83% evidence | 11.2/25 ROCE 2.8% · OPM 15.5% 76% evidence | 6.2/20 P/E 116.6× · PEG 2.64 65% evidence | 6.5/20 RS sector -4.3% · RS bench 1.5% · 1Y 81.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 11.2 + 6.2 + 6.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Universal Display CorporationOLED | 44.5/100Thin evidence · provisional56% evidence | ASLEEP | 14.1/35 Revenue — · PAT — · OPM change -11.8 pp 39% evidence | 13.7/25 ROCE 3% · OPM 30.1% 76% evidence | 11.3/20 P/E 21× · PEG — 15% evidence | 5.4/20 RS sector -41.6% · RS bench -32.5% · 1Y -46.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 13.7 + 11.3 + 5.4 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Flex Ltd.FLEX | 43.6/100Mixed-negative evidence81% evidence | ASLEEP | 14.4/35 Revenue 12.3% · PAT 9.2% · OPM change 0.2 pp 83% evidence | 11.4/25 ROCE 3.7% · OPM 4.9% 76% evidence | 4.7/20 P/E 56.6× · PEG 4.17 65% evidence | 13.1/20 RS sector 8.3% · RS bench 14.2% · 1Y 84%5 of 12 weeks ahead 100% evidence |
| Exact sum: 14.4 + 11.4 + 4.7 + 13.1 = 43.6 · Decision use: Price leads the evidence: RS versus the benchmark is 14.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21Vicor CorporationVICR | 43.5/100Thin evidence · provisional56% evidence | ASLEEP | 16.9/35 Revenue — · PAT — · OPM change 15.1 pp 39% evidence | 13.7/25 ROCE 4.8% · OPM 14.9% 76% evidence | 8.7/20 P/E 121.7× · PEG — 15% evidence | 4.2/20 RS sector -5.3% · RS bench -2.2% · 1Y 247.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 13.7 + 8.7 + 4.2 = 43.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22TTM Technologies, Inc.TTMI | 42.8/100Mixed-negative evidence66% evidence | ASLEEP | 19.9/35 Revenue 25.4% · PAT 84.9% · OPM change 0.9 pp 53% evidence | 10.1/25 ROCE 2.6% · OPM 8.6% 57% evidence | 9.2/20 P/E 47.7× · PEG 1.82 65% evidence | 3.6/20 RS sector -7% · RS bench -2.6% · 1Y 118.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 10.1 + 9.2 + 3.6 = 42.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23OSI Systems, Inc.OSIS | 35.9/100Mixed-negative evidence66% evidence | ASLEEP | 12.4/35 Revenue 7% · PAT 7.8% · OPM change -1 pp 53% evidence | 12.2/25 ROCE 3% · OPM 11.7% 57% evidence | 5.6/20 P/E 30.3× · PEG 4.61 65% evidence | 5.7/20 RS sector -33.5% · RS bench -24.7% · 1Y -14.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 12.2 + 5.6 + 5.7 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24LSI Industries Inc.LYTS | 34.7/100Thin evidence · provisional60% evidence | ASLEEP | 14.2/35 Revenue 11.5% · PAT 17.4% · OPM change -2 pp 53% evidence | 8.8/25 ROCE 0.9% · OPM 2.7% 57% evidence | 6.8/20 P/E 24.8× · PEG 3.44 65% evidence | 4.9/20 RS sector -20.5% · RS bench -11.9% · 1Y -13%3 of 12 weeks ahead 70% evidence |
| Exact sum: 14.2 + 8.8 + 6.8 + 4.9 = 34.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Ouster, Inc.OUST | 49.7/100Thin evidence · provisional48% evidence | ASLEEP | 22.2/35 Revenue 57.6% · PAT — · OPM change 33.5 pp 40% evidence | 5.7/25 ROCE -8% · OPM -39.5% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.8/20 RS sector -0.5% · RS bench 7.9% · 1Y -1.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 5.7 + 10 + 11.8 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Richardson Electronics, Ltd.RELL | 48.8/100Thin evidence · provisional50% evidence | ASLEEP | 16.4/35 Revenue — · PAT — · OPM change -1.3 pp 39% evidence | 6.6/25 ROCE 1.9% · OPM 2.7% 76% evidence | 10.4/20 P/E 38.6× · PEG — 15% evidence | 15.4/20 RS sector 4.9% · RS bench 13% · 1Y 64.3%7 of 12 weeks ahead 70% evidence |
| Exact sum: 16.4 + 6.6 + 10.4 + 15.4 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Bel Fuse Inc.BELFB | 46.1/100Thin evidence · provisional50% evidence | ASLEEP | 15.9/35 Revenue — · PAT — · OPM change -3.1 pp 39% evidence | 13.8/25 ROCE 4% · OPM 13.3% 76% evidence | 9.1/20 P/E 85.2× · PEG — 15% evidence | 7.3/20 RS sector -6.9% · RS bench -0.1% · 1Y 65.1%2 of 12 weeks ahead 70% evidence |
| Exact sum: 15.9 + 13.8 + 9.1 + 7.3 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28FabrinetFN | 43.4/100Thin evidence · provisional46% evidence | BASING | 18.4/35 Revenue — · PAT — · OPM change 0.6 pp 24% evidence | 14.2/25 ROCE 5.6% · OPM 10.1% 57% evidence | 9.7/20 P/E 47× · PEG — 15% evidence | 1.1/20 RS sector -33.9% · RS bench -27.6% · 1Y 2.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 14.2 + 9.7 + 1.1 = 43.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29LightPath Technologies, Inc.LPTH | 41.7/100Thin evidence · provisional42% evidence | ASLEEP | 21.5/35 Revenue 87.9% · PAT — · OPM change 15.5 pp 40% evidence | 6.1/25 ROCE -4.4% · OPM -22.2% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -26.3% · RS bench -20.4% · 1Y 29.7%3 of 12 weeks ahead 70% evidence |
| Exact sum: 21.5 + 6.1 + 10 + 4.1 = 41.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Syntec Optics Holdings, Inc.OPTX | 32.9/100Thin evidence · provisional45% evidence | ASLEEP | 11.1/35 Revenue 0% · PAT — · OPM change -19.4 pp 40% evidence | 6.2/25 ROCE -5.6% · OPM -11.9% 57% evidence | 8.6/20 P/E 123× · PEG — 15% evidence | 7.0/20 RS sector -5.2% · RS bench -3.6% · 1Y 274.7%2 of 12 weeks ahead 70% evidence |
| Exact sum: 11.1 + 6.2 + 8.6 + 7 = 32.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Allient Inc.'s stock price today?
Allient Inc. trades at $94.8, +103.4% over the past year. The company is valued at $2.0 B. The stock sits at 74% of its 52-week range of $44–$113, +26.5% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. — as of 17 September 2026.
What were Allient Inc.'s latest quarterly results?
Allient Inc. reported revenue of $0.1 B and net profit of $0.0 B for the Mar 26 quarter. Earnings per share were $0.32. The operating margin was 7.1%, 0.6 pp lower than a year earlier. — as of 17 September 2026.
What is Allient Inc.'s revenue?
Allient Inc. reported revenue of $0.1 B in the Mar 26 quarter, +7.7% year on year. For the full FY25 fiscal year, revenue was $0.6 B (+3.8%). Over the last 4 years revenue compounded at 8.3% a year. — as of 17 September 2026.
What is Allient Inc.'s profit?
Allient Inc. earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The operating margin ran 7.1% in the latest quarter. — as of 17 September 2026.
What is Allient Inc.'s market cap?
Allient Inc.'s market capitalisation is $2.0 B at a stock price of $94.8. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
Does Allient Inc. pay a dividend?
Yes — Allient Inc. declared $0.03 per share for Mar 26, and $0.12 per share across the last four reported quarters. The latest quarter is up 20.0% on the same quarter a year earlier. — as of 17 September 2026.
What is Allient Inc.'s dividend per share?
Allient Inc.'s most recently declared dividend is $0.03 per share for Mar 26, giving $0.12 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is Allient Inc.'s dividend yield?
Allient Inc.'s trailing dividend yield is 0.13%: $0.12 declared per share across the last four reported quarters, against a share price of $94.8. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
How is Allient Inc. performing?
Allient Inc.'s latest readings are below. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Allient Inc. in?
Turning around — profit growth swung from −66.7% at the trough to +200.0%, a 3-quarter improving streak, ROCE holding at 7.7%. The read comes from the last 12 quarters of growth (revenue growth +7.7% latest, profit growth +200.0% latest, eps growth +142.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Allient Inc. beating the market?
Not lately — on a trailing-13-week view Allient Inc. is currently behind the S&P 500 (1 week and counting; last ahead the week of 2026-09-11), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.2 years the stock moved +146% against the S&P 500's +21% — ahead of the index over the full window. — as of 17 September 2026.
Will Allient Inc.'s stock price go up?
This page publishes no price forecast for Allient Inc. What it measures instead: the stock price is $94.8. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against Allient Inc.?
Somewhat — short interest is 3.6% of Allient Inc.'s tradable float, about 2.0 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Allient Inc. have too much debt?
It is moderate — Allient Inc.'s debt-to-equity is 0.63. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Allient Inc.'s capex?
Allient Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.
What is Allient Inc.'s cash flow?
Allient Inc. generated $0.1 B of operating cash flow in FY25 and $0.1 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Allient Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 300% of Allient Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.1 B against reported profit of $0.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Allient Inc.?
On the balance sheet, the Z-score reads 4.26 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Allient Inc. in its business cycle?
Allient Inc.'s FY25 operating margin was 7.3%, against a 5-year band of 5.7%–7.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 7.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Allient Inc. story?
The sharpest disagreement: the price moved +103.4% in a year while annual EPS moved +67.1% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Allient Inc. a stock worth studying right now?
This is not investment advice. The machine read: Allient Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!